<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunoliposomes (ILs) can be constructed to target the epidermal growth factor receptor (EGFR) to provide efficient intracellular drug delivery in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that this approach might be able to overcome drug resistance mechanisms, which remain an important obstacle to better outcomes in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>ILs were evaluated in vitro and in vivo against EGFR-overexpressing pairs of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells (HT-29 and <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231) that either lack or feature the multidrug resistance (mdr) phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>In multidrug-resistant cell lines, ILs loaded with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DOX) produced 19-216-fold greater cytotoxicity than free DOX, whereas in nonresistant cells, immunoliposomal cytotoxicity of DOX was comparable with that of the free drug </plain></SENT>
<SENT sid="4" pm="."><plain>In intracellular distribution studies, free DOX was efficiently pumped out of the multidrug-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, whereas immunoliposomal DOX leads to 3.5-8 times higher accumulation of DOX in the cytoplasm and 3.5-4.9 times in the nuclei compared with the free drug </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, in vivo studies in the <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231 Vb100 xenograft model confirmed the ability of anti-EGFR ILs-DOX to efficiently target multidrug-resistant cells and showed impressive antitumor effects, clearly superior to <z:hpo ids='HP_0000001'>all</z:hpo> other treatments </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, ILs provide efficient and targeted drug delivery to EGFR-overexpressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and are capable of completely reversing the multidrug-resistant phenotype of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
</text></document>